Physician profile
Samuel A Farbstein
NPI 1629084116
$1,033.62
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $749 · 2020: $119 · 2021: $165.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $255.83 | 2019-2021 | |
| Novo Nordisk INC | $116.06 | 2019 | |
| Janssen Pharmaceuticals, INC | $114.15 | 2019-2020 | |
| Pfizer INC. | $111.13 | 2019 | |
| Eisai INC. | $97.89 | 2021 | |
| Amarin Pharma, INC. | $97.10 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $41.10 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $39.27 | 2019 | |
| Currax Pharmaceuticals LLC | $35.03 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $33.58 | 2019 | |
| Astellas Pharma US INC | $30.59 | 2021 | |
| Janssen Scientific Affairs, LLC | $25.28 | 2020 | |
| Sanofi-Aventis U.S. LLC | $21.35 | 2019 | |
| Lilly USA, LLC | $15.26 | 2020 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$325.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Farbstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.